Scientific Reports,
Journal Year:
2025,
Volume and Issue:
15(1)
Published: Feb. 6, 2025
To
improve
the
treatment
outcome
and
survival
of
patients
with
advanced
high-grade
serous
carcinoma
(HGSC),
prognostic
biomarkers
for
assessing
feasibility
complete
(R0)
or
optimal
(R1)
primary
cytoreductive
surgery
are
needed.
Additionally,
predicting
response
to
neoadjuvant
chemotherapy
(NACT)
in
inoperable
disease
could
help
stratify
tailored
therapy
personalised
approach.
Such
promising
extracellular
vesicles
(EVs),
which
present
ascites
plasma
available
minimally
invasive
liquid
biopsy.
EV
concentration
molecular
profile
have
been
at
forefront
research
field
many
years
now,
but
recent
studies
highlighted
importance
size
distribution.
Our
study
aimed
evaluate
potential
distribution
pretreatment
samples
from
HGSC
as
biomarkers.
In
our
prospective
cohort
study,
nanoparticle
tracking
analysis
(NTA)
was
used
determine
characteristics
paired
37
HGSC.
Patients
were
treated
followed
by
adjuvant
(ACT)
(N
=
15)
NACT
interval
debulking
(IDS)
when
cytoreduction
not
feasible
22).
The
correlations
outcome,
progression-free
(PFS)
overall
(OS)
analysed.
We
found
a
significant
correlation
between
residual
after
surgery.
Larger
EVs
correlated
worse
resection
success
A
D10
value
score
(CRS)
observed.
smaller
better
response.
Receiver
operating
characteristic
(ROC)
curve
revealed
excellent
performance
prediction
suboptimal
(R2)
near-complete
(CRS
3)
There
mean
diameter,
D90
proportion
medium/large
(>
200
nm)
those
plasma.
On
other
hand,
there
no
D50
values
fluid
samples.
results
indicate
that
has
predict
smallest
might
NACT.
future,
analyses
size-dependent
cargo
provide
more
insight
into
their
biological
functions
predictive
Frontiers in Immunology,
Journal Year:
2023,
Volume and Issue:
14
Published: March 8, 2023
The
conventional
therapeutic
approaches
to
treat
autoimmune
diseases
through
suppressing
the
immune
system,
such
as
steroidal
and
non-steroidal
anti-inflammatory
drugs,
are
not
adequately
practical.
Moreover,
these
regimens
associated
with
considerable
complications.
Designing
tolerogenic
strategies
based
on
stem
cells,
their
extracellular
vesicles
(EVs)
seems
open
a
promising
path
managing
diseases’
vast
burden.
Mesenchymal
stem/stromal
cells
(MSCs),
dendritic
regulatory
T
(Tregs)
main
cell
types
applied
restore
status;
MSCs
play
more
beneficial
role
due
amenable
properties
extensive
cross-talks
different
cells.
With
existing
concerns
about
employment
of
new
cell-free
paradigms,
EV-based
therapies,
gaining
attention
in
this
field.
Additionally,
EVs’
unique
have
made
them
be
known
smart
immunomodulators
considered
potential
substitute
for
therapy.
This
review
provides
an
overview
advantages
disadvantages
cell-based
methods
treating
diseases.
study
also
presents
outlook
future
EVs
implemented
clinics
patients.
Molecular Pharmaceutics,
Journal Year:
2023,
Volume and Issue:
20(8), P. 3829 - 3842
Published: July 6, 2023
Small
extracellular
vesicles
(sEVs)
are
produced
by
most
cells
and
play
an
important
role
in
cell-to-cell
communication
maintaining
cellular
homeostasis.
Their
ability
to
transfer
biological
cargo
target
makes
them
a
promising
tool
for
cancer
drug
delivery.
Advances
sEV
engineering,
EV
mimetics,
ligand-directed
targeting
have
improved
the
efficacy
of
anticancer
delivery
functionality.
EV-based
RNA
interference
hybrid
miRNA
also
been
extensively
used
various
preclinical
models.
Despite
these
developments,
gaps
still
exist
our
understanding
using
sEVs
treat
solid
tumor
malignancies
effectively.
This
article
provides
overview
last
five
years
research
its
current
status
efficient
targeted
elimination
cells,
which
could
advance
bring
formulations
into
clinical
use.
Scientific Reports,
Journal Year:
2025,
Volume and Issue:
15(1)
Published: Feb. 6, 2025
To
improve
the
treatment
outcome
and
survival
of
patients
with
advanced
high-grade
serous
carcinoma
(HGSC),
prognostic
biomarkers
for
assessing
feasibility
complete
(R0)
or
optimal
(R1)
primary
cytoreductive
surgery
are
needed.
Additionally,
predicting
response
to
neoadjuvant
chemotherapy
(NACT)
in
inoperable
disease
could
help
stratify
tailored
therapy
personalised
approach.
Such
promising
extracellular
vesicles
(EVs),
which
present
ascites
plasma
available
minimally
invasive
liquid
biopsy.
EV
concentration
molecular
profile
have
been
at
forefront
research
field
many
years
now,
but
recent
studies
highlighted
importance
size
distribution.
Our
study
aimed
evaluate
potential
distribution
pretreatment
samples
from
HGSC
as
biomarkers.
In
our
prospective
cohort
study,
nanoparticle
tracking
analysis
(NTA)
was
used
determine
characteristics
paired
37
HGSC.
Patients
were
treated
followed
by
adjuvant
(ACT)
(N
=
15)
NACT
interval
debulking
(IDS)
when
cytoreduction
not
feasible
22).
The
correlations
outcome,
progression-free
(PFS)
overall
(OS)
analysed.
We
found
a
significant
correlation
between
residual
after
surgery.
Larger
EVs
correlated
worse
resection
success
A
D10
value
score
(CRS)
observed.
smaller
better
response.
Receiver
operating
characteristic
(ROC)
curve
revealed
excellent
performance
prediction
suboptimal
(R2)
near-complete
(CRS
3)
There
mean
diameter,
D90
proportion
medium/large
(>
200
nm)
those
plasma.
On
other
hand,
there
no
D50
values
fluid
samples.
results
indicate
that
has
predict
smallest
might
NACT.
future,
analyses
size-dependent
cargo
provide
more
insight
into
their
biological
functions
predictive
